PT  - JOURNAL ARTICLE
AU  - McGarvey, Lorcan
AU  - Morice, Alyn
AU  - Smith, Jacky
AU  - Birring, Surinder
AU  - Chuecos, Ferran
AU  - Seoane, Beatriz
AU  - Jarreta, Diana
TI  - The effect of twice-daily aclidinium bromide on cough and sputum in patients with COPD: Results from phase III studies
DP  - 2014 Sep 01
TA  - European Respiratory Journal
PG  - P920
VI  - 44
IP  - Suppl 58
4099  - http://erj.ersjournals.com/content/44/Suppl_58/P920.short
4100  - http://erj.ersjournals.com/content/44/Suppl_58/P920.full
SO  - Eur Respir J2014 Sep 01; 44
AB  - BackgroundChronic cough and sputum production are troublesome symptoms in COPD. Three Phase III studies assessed the effect of aclidinium 400 µg twice-daily (BID) on cough and sputum severity in patients with moderate-to-severe COPD (not selected for these symptoms).MethodThese were randomized, double-blind, placebo-controlled studies. Patients were randomized to BID placebo, aclidinium 200 µg or aclidinium 400 µg (ACCORD COPD I [12 weeks] and ATTAIN [24 weeks]) and placebo, aclidinium 400 µg or tiotropium 18 µg once-daily (LAS39; 6 weeks). Changes from baseline in EXAcerbations of Chronic pulmonary disease Tool-Respiratory Symptoms (E-RS) total and cough/sputum domain scores and morning/night-time cough and phlegm symptoms (symptom questionnaires) were assessed.ResultsThe ITT population included 559 (mean age 64 years; 53% male; mean post-bronchodilator FEV1 54% predicted), 819 (62 years; 67% male; FEV1 57% predicted) and 414 (62 years; 67% male; FEV1 56% predicted) patients in ACCORD, ATTAIN, and LAS39, respectively.E-RS cough/sputum domain scores were lower with aclidinium 400 µg than placebo (both p<0.01; Table). Morning and night-time cough severity, morning difficulty bringing up phlegm and night-time sputum production were also reduced with aclidinium 400 µg (all p<0.05 vs placebo; Table).ConclusionsAclidinium 400 µg BID may provide improvements in cough and sputum expectoration.